The hypothalamic-pituitary-ovarian axis in patients with endometriosis is suppressed by leuprolide acetate but not by danazol*
|
|
- Nigel Bruce
- 6 years ago
- Views:
Transcription
1 FERTILITY AND STERILITY Copyright" 1994 The American Fertility Society Printed on acid-free paper in U. S. A. The hypothalamic-pituitary-ovarian axis in patients with endometriosis is suppressed by leuprolide acetate but not by danazol* Masahiro Sakata, M.D.t Shiro Ohtsuka, M.D., Ph.D. Hirohisa Kurachi, M.D., Ph.D. Akira Miyake, M.D., Ph.D. Naoki Terakawa, M.D., Ph.D.* Osamu Tanizawa, M.D., Ph.D. Department of Obstetrics and Gynecology, Osaka University Medical School, Suita, Osaka, Japan Objective: To investigate the effects ofleuprolide acetate (LA), a GnRH agonist (GnRH-a), and of danazol on the hypothalamic-pituitary-ovarian axis in patients with endometriosis. Design: Ten patients were divided into LA and danazol treatment groups. Measures: Serum levels ofe2, immunoreactive and bioactive LH, pulsatility oflh, and gonadotropins release by GnRH. Changes in serum E2levels by hmg administration during LA treatment. Results: Serum E2 level decreased to near castrated levels during the LA treatment, while it remained unchanged during the danazol treatment. Leuprolide acetate administration resulted in a significant suppression of the serum level of bioactive LH, of the pulsatility of LH release, of the pituitary response to GnRH injection, and of the elevation in the serum E2 level by hmg administration, but danazol treatment did not show these suppressive effects. Conclusion: Our results suggest that the hormonal actions of LA and danazol on endometriosis are different from each other, especially in the suppression of serum E2 level. Fertil Steril 1994;61:432-7 Key Words: Endometriosis, leuprolide acetate, GnRH agonist, danazol, serum E2 level As many as 30% of women, who complain of dysmenorrhea and pelvic pain, have endometriosis, and >50% of women with unexplained infertility are diagnosed with endometriosis by laparoscopy. The incidence of endometriosis tends to be increasing (1). It is well known that ovarian estrogen and progestogen stimulate endometriosis and oophorectomy causes regression of the lesion (2). Therefore, one of the mechanisms of medical treatment Received June 21, 1993; revised and accepted October 29, * Presented in part at the 41th Japanese Congress of Gynecology and Obstetrics, Okayama, Japan, April 2 to 4,1989. t Reprint requests: Masahiro Sakata M.D., Department of Obstetrics and Gynecology, Osaka University Medical School, 2-2, Yamadaoka, Suita, Osaka, Japan 565. :j: Present address: Department of Obstetrics and Gynecology, Tottori University School of Medicine, Yonago, Tottori, Japan. 432 Sakata et al. Hormone action of LA and danazol for endometriosis depends on the suppression of ovarian steroidogenesis. Because it has been shown that GnRH agonist (GnRH-a) results in some physiological changes characteristic of medical castration (3), GnRH-a have been evaluated as a medical regimen for endometriosis. Gonadotropin-releasing hormone agonist induces desensitization of pituitary gland for GnRH and decreases the serum level of bioactive LH (4,5), resulting in the reduction of ovarian estrogen production. However, the detailed mechanism(s) of gonadal steroidogenesis suppression has not been fully elucidated. Danazol, a synthetic derivative of 17 a-ethynyltestosterone, has been widely used in the treatment of endometriosis (2). Although this compound is effective in treating the endometriosis (2), its pharmacological mechanism(s) is not completely elucidated. At first, danazol was introduced as an Fertility and Sterility
2 antigonadotropic agent (2), and its suppressive effect on gonadotropin secretion was considered to cause the reduction of ovarian steroidogenesis, followed by endometrial atrophy. However, its antigonadotropic effect has been questioned because the basal gonadotropin level was reported not to be altered (5). There are now several studies that suggest that danazol exerts its therapeutic action by inhibiting enzyme activities in the steroidogenesis (2) or by binding to multiple steroid hormone receptors in target tissues (2, 6), especially in the endometrium. In this study, we examined not only basal serum levels of E2, immunoreactive LH, and FSH but also the serum level of bioactive LH, the changes in the pulsatility of gonadotropin secretion, and the response of gonadotropins to GnRH during leuprolide acetate (LA, GnRH -a) and danazol treatments in 10 women with endometriosis. Changes in serum E2 levels after hmg administration was investigated before and during LA in four patients. tion, and the pituitary response to GnRH injection were studied at the early follicular phase of the pretreatment cycle and at the 12th week of both treatments. Pulsatility of LH secretion was examined in blood samples obtained at 15-minute interval for 4 hours (9:00 A.M. to 1:00 P.M.). A pulse was defined as an increase in LH concentration of :2:2 SD from a nadir (within 30 minutes before the peak) (7). To evaluate the effects of LA and danazol on the pituitary response to exogenous GnRH, 100 J.Lg of GnRH (gonadorelin acetate; Tanabe Seiyaku Company Limited, Tokyo, Japan) was injected IV and blood samples were taken for 2 hours. Human menopausal gonadotropin (150 IV; Organon, Oss, The Netherlands) was administered intramuscularly for 3 consecutive days to estimate the ovarian response before and during LA treatment (hmg test). Blood was obtained on 0,2, and 4 days of the hmg test to determine serum E2 concentrations by RIA. MATERIALS AND METHODS Subjects and Protocol Subjects in this study were 10 regularly menstruating women between 29 and 40 years of age. Endometriosis was diagnosed by laparoscopy in all subjects. Before the study, the guideline for the protocol of this study was approved by Osaka V niversity Medical School, and informed consent was obtained from all subjects. Ten women were divided into two groups. Five women were treated with SC injection of 3.75 mg of LA depot (Takeda Chemical Industry Limited, Osaka, Japan) within 3 days of menstrual period followed by injections once per 4 weeks for 24 weeks. The other five women were treated with danazol (200 mg by mouth, 2 times per day) (Tokyo Tanabe Company Limited, Tokyo, Japan), started on the 1st day of menstrual period and then continuously for :2:16 weeks. None of the patients received other hormonal medications for :2:6 months before and during the period of study. They recorded daily basal body temperature (BBT) during a pretreatment cycle and consecutive treatment period. The blood samples for basal serum levels of E2, LH, and FSH were taken at the early follicular phase of a pretreatment cycle, and every 2 or 4 weeks during the treatment. Blood samples were always taken before LA SC injection. The levels of bioactive LH, the pulsatile patterns of LH secre- Hormone Assays The sera were prepared from blood samples and frozen at -20 C until analyses ofe2, immunoreactive LH, bioactive LH, and FSH. Serum concentrations of E2, immunoreactive LH, and FSH were measured by RIA as described previously (8-10). The sensitivity of RIA of these hormones was as follows: E2, 3 pg per tube; LH, 0.2 miv Second International Reference Preparation of hcg (2nd IRP-hCG) per tube; and FSH, 0.1 miv 2nd IRPhMG per tube. The interassay and intra-assay coefficients of variation (CV) were 9.0% and 8.0% for E2, 10.3% and 8.3% for LH, and 9.6% and 9.0% for FSH, respectively. Serum bioactive LH was determined by measuring the T production in dispersed rat Leydig cells in vitro as described previously (9). Leydig cells were prepared from adult rat testes by collagenase digestion and suspended in Medium 199 containing 0.1 % bovine serum albumin (BSA). Aliquots of Leydig cell suspensions were incubated with various concentrations of standard LH (1st IRP LH code 68/ 40) or with sera at 37 C for 3 hours under 95% air and 5% CO2 with shaking. After the incubation, the mixtures were centrifuged at 1,000 X g for 15 minutes, and aliquots of supernatants were diluted with phosphate buffered saline (PBS) containing 1 % BSA for T RIA. The interassay and intra-assay CV of T assay were 9.4% and 9.0%, respectively. Bioactive LH in sera was assayed by measuring T Sakata et al. Hormone action of LA and danazol 433
3 production in comparison with that of a standard preparation. The interassay and intra-assay CV of bioactive LH were 14.0% and 8.0%, respectively. Statistical Analysis All values were expressed as means ± SE. Analysis of variance was performed for the statistical analysis if necessary, followed by Student's t-test. RESULTS All 10 patients remained anovulatory during the LA and danazol treatments. Their BBT was biphasic in the pretreatment cycle and monophasic during both treatments. Serum E2 levels markedly increased in three of five patients in the 2nd week of LA treatment. In the 4th week, serum E2 levels decreased to near castrated levels (22.9 ± 4.5 pg/ml) (conversion factor to SI unit, 3.671) in all patients, and remained at this level thereafter (Fig. la). All five women com- plained of hot flushes during the LA treatment. On the contrary, the serum E2levels in the five women remained unchanged during the danazol treatment (Fig. IB). None of them complained of hot flushes. During 24 weeks of the LA treatment, basal levels of serum LH and FSH remained unchanged in all patients (Fig. lc), in contrast to the marked reduction in serum levels of E2. Basal levels of immunoreactive LH and FSH also remained unchanged in all five patients during 20 weeks of danazol treatment (Fig. ID). Immunoreactive LH level at the 12th week of LA treatment (n = 5) was 12.5 ±1.9 miu/ml, which was slightly but not significantly lower than that in the pretreatment cycle (18.5 ± 3.2 miu/ml). However, the level of bioactive LH at the 12th week of LA treatment (7.7 ± 2.0 miu/ml) was significantly (P < 0.05) lower than that in the pretreatment cycle (22.4 ± 5.0 miu/ml). These findings suggested that LA treatment suppressed the level of bioactive LH but not the immunoreactive LH. Levels of A o a '0 '2 '4 '6 '8 20 (w) D. 40 ~30..s O~ ~ o (w) ~30~ 3 20 ~.--.!10: ~~= J:...--=.~----. ~ OL ~-- o (w) -_40...J E 30 c. 1 ~20 -.~ "3,~f?=:.::: =- : ;;;; :;4l , (-J ~30 I~~~ o (w) Figure 1 Serum levels of E2 before and during 24 weeks of LA (A) and 20 weeks of danazol (B) treatments (conversion factor to SI unit, 3.671) and of immunoreactive LH and FSH before and during 24 weeks of LA (C) and 20 weeks of danazol (D) treatments in each patient with endometriosis. Blood samples were obtained in the early follicular phase in a pretreatment cycle (0 week) and every 2 or 4 weeks during the treatments (n = 5 in each group). 434 Sakata et al. Hormone action of LA and danazol Fertility and Sterility
4 b!~~,~~ ~ r 1;,. ~-; ~:~~!~~ Figure 2 Pulsatile patterns of LH secretion in 4 patients before (left columns) and during (right columns, the 12th week) LA (A) and danazol (B) treatments. Blood samples were obtained at 15-minute intervals from 9:00 A.M. through 1:00 P.M. The pulse was defined as described in Materials and Methods.!3G' ~2 ~ -'\"iv~ '~3 3 1 Case 3... F~~ 1 _ ~ase4 JI:~C=:: o (.) 13~l~!~!0Jl~ o <-.) immunoreactive and bioactive LH at the 12th week of danazol treatment (n = 5) were 16.2 ± 2.4 and 32.0 ± 3.3 miu/ml, respectively, both of which were not significantly different from those in the pretreatment cycle (15.3 ± 2.4 and 28.2 ± 1.6 miui ml, respectively). The pulsatile patterns of pituitary LH release before and during LA treatment were studied in blood samples obtained at 15-minute interval for 4 hours. Figure 2A shows individual data obtained in four patients before and during LA treatment. Pulsatile secretion of LH (2.3 ± 0.3 pulses per 4 hours) in the pretreatment cycle disappeared at the 12th week of LA treatment. Contrary to these results in patients treated with LA, pulsatile secretion oflh (2.3 ± 0.3 pulses per 4 hours) observed in the pretreatment cycle were not altered at the 12th week of danazol treatment (Fig. 2B). The pituitary response to 100 Jig of GnRH, administered IV in the pretreatment and during LA treatment, is shown in Figure 3A. Gonadotropin release by 100 Jig of GnRH at the 12th week of LA treatment was markedly suppressed when compared with that in the pretreatment cycle. On the contrary, the gonadotropin release by 100 Jig of GnRH during danazol treatment was not significantly different from that in the pretreatment cycle (Fig.3B). Because LA, but not danazol, suppressed the serum E2 level during treatment, the ability of ovaries to secrete E2 in the patients before and during the LA treatment was evaluated by hmg test. Data from four patients before and at the 12th week of LA treatment showed that the increase in serum E2 levels in response to hmg during LA treatment A. 120 :; E '3 l 90 I 60 'i' en... B.120 :; E '3 l 90 :; 120 ~ ~ :::: :t en :; ~! :t en... I 'i'.j o'~------~------c (m) o Figure 3 Pituitary response to 100 /lg of GnRH administration in the pretreatment cycle (left), and during (right) LA (A) (n = 5) and danazol (B) (n = 4) treatments. Gonadotropin-releasing hormone (100 /lg) was administered, and blood samples were taken before and 30, 60, and 120 minutes after GnRH administration. Serum levels of LH and FSH were determined by RIA. Sakata et al. Hormone action of LA and danazol 435
5 were 42 ± 15 and 51 ± 12 pg/ml on days 2 and 4, respectively, which were significantly (P < 0.01) lower than those in a pretreatment cycle (258 ± 70 and 493 ± 129 pg/ml, respectively) (conversion factor to SI unit, 3.671). DISCUSSION Serum E2 levels are markedly reduced to near castrated levels during GnRH -a treatment, and it is suggested that the effects of GnRH -a on endometriosis are mainly through the reduction of E2 levels (8,11). Although suppression ofe2 is reported to be associated with the decrease in serum levels of immunoreactive LH (11), neither the serum levels of immunoreactive LH nor FSH significantly declined below the pretreatment levels in this study and in our previous study (8). These data suggested that suppressed serum E2 levels were not caused by the reduction in serum immunoreactive gonadotropins levels during GnRH -a treatment, and these results were consistent with the previous data in patients with prostate cancer (12). We have shown that the serum levels of bioactive LH at the 12th week of GnRH -a treatment were significantly lower than those in the pretreatment cycle. Similar data have been reported in women with endometriosis (8) and polycystic ovarian disease (PCOD) (4). Ovarian follicular maturation requires pulsatile gonadotropin secretion (8). Our results suggest that the absence of LH pulsatility may be a cause to decrease the serum E2 levels during LA treatment in addition to the reduction in bioactive LH levels. The fact that LH release in response to GnRH was reduced during LA treatment may explain the elimination of the LH pulsatility. Another possible mechanism by which GnRH-a suppresses estrogen production is a direct inhibition of ovarian steroidogenesis; it has been reported that GnRH -a directly decreases ovarian LH receptor level (13) and that GnRH-a impairs steroidogenesis in cultured human granulosa cells (14). In this study, we found that hmg-induced estrogen secretion was reduced during LA treatment. These results were different from those of our previous report (8) that hmg-induced estrogen secretion was not reduced during buserelin treatment. Other reports showed that the ovarian response to exogenous gonadotropins was reduced in patients receiving GnRH-a (15, 16). The discrepancy in the effects of LA and buserelin on the hmg test may result from the fact that LA (SC injection of depot formula) is more potent than buserelin (nasal ad- ministration) to inhibit ovarian steroidogenesis by gonadotropins. All these results suggest that LA has potent inhibitory effects on the hypothalamic-pituitary-ovarian axis. Serum E2 levels during danazol treatment are reported to increase (17), to decrease (18), or not to change (19, 20). In our results, danazol did not change the serum E2 nor serum gonadotropin levels in consistent with the previous reports (5). In addition, we have demonstrated that danazol administration did not change the serum levels ofbioactive LH. The result in this study that pituitary gonadotropin secretion by GnRH administration was not altered during danazol treatment was consistent with the previous report (19). Our result, that the LH pulses did not change before and during danazol administration (400 mg/d), was not consistent with a previous one (21) that the mean frequency of LH pulses decreased. However, they treated the patients with 800 mg/d of danazol, and the different dosage of danazol may explain the inconsistency of their data with ours. All of our data suggest that danazol has very little effect on the hypothalamic-pituitary-ovarian axis. It is also known that danazol administration directly induces endometrial atrophy in 4 weeks without decreasing the serum E2 level (22). Finally, these data suggest that the mechanisms of action of GnRH -a and danazol on endometriosis are different from each other. Moreover, it is reported that combination of LA and danazol has more profound effect on the regression of the experimental endometriosis tissue than LA or danazol alone in the rat (10). These considerations suggest that the combined therapy of GnRH -a and danazol may have more efficient therapeutic potency in patients with endometriosis. REFERENCES 1. Houston DE. Evidence for the risk of pelvic endometriosis by age, race and socioeconomic status. Epidemiol Rev 1984;6: Barbieri RL, Ryan KJ. Danazol: endocrine pharmacology and therapeutic application. Am J Obstet Gynecol 1981;141: Lemay A, Quesnel G. Potential new treatment of endometriosis: reversible inhibition of pituitary-ovarian function by chronic intranasal administration of a luteinizing hormone-releasing hormone (LH-RH) agonist. Fertil Steril 1982;38: Meldrum DR, Tsao Z, Monroe SE, Braunstein GD, Sladek J, Lu JKH, et al. Stimulation of LH fragments with reduced bioactivity following GnRH agonist administration in women. J Clin Endocrinol Metab 1984;58: Sakata et al. Hormone action of LA and danazol Fertility and Sterility
6 5. Andrews MC, Wentz AC. The effects of Danazol on gonadotropins and steroid blood levels in normal and anovulatory women. Am J Obstet GynecoI1975;121: TamayaT, Wada K, FujimotoJ, YamadaT, OkadaH. Danazol binding to steroid receptors in human uterine endometrium. Fertil Steril 1984;41: Buckman MT, Peake GT, Srivastava L. Patterns ofspontaneous LH release in normo- and hyperprolactinaemic women. Acta EndocrinoI1981;97:305-1O. 8. Ohtsuka S, Terakawa N, Shimizu I, Sakata M, Mizutani T, Miyake A, et al. Studies on GnRH agonist suppression of estrogen production in patients with endometriosis. Endocrinol Japon 1989;36: Sakata M, Tasaka K, Kurachi H, Terakawa N, Miyake A, Tanizawa O. Changes ofbioactive luteinizing hormone after laparoscopic ovarian cautery in patients with polycystic ovarian syndrome. Fertil Steril 1990;53: Sakata M, Terakawa N, Mizutani T, Tanizawa 0, Matsumoto K, Terada N, et al. Effects of danazol, gonadotropinreleasing hormone agonist, and a combination of danazol and gonadotropin-releasing hormone agonist on experimental endometriosis. Am J Obstet Gynecol 1990;163: Schriock E, Monroe SE, Henzl M, Jaffe RB. Treatment of endometriosis with a potent agonist of gonadotropin-releasing hormone (nafarelin). Fertil Steril 1985;44: Rajfer J, Handelsman DJ, Crum A, Steiner B, Peterson M, Swerdloff RS. Comparison of the efficacy of subcutaneous and nasal spray Buserelin treatment in suppression of testicular steroidogenesis in men with prostate cancer. Fertil Steril1986;46: Guerrero HE, Stein P, Asch RH, de Fried EP, Tesone M. Effect of a gonadotropin-releasing hormone agonist on luteinizing hormone receptors and steroidogenesis in ovarian cells. Fertil Steril 1993;59: Parinaud J, Beaur A, Bourreau E, Vieitez G, Pontonnier G. Effect of a luteinizing hormone-releasing hormone agonist (Buserelin) on steroidogenesis of cultured human preovulatory granulosa cells. Fertil Steril 1988;50: Lejeune B, Barlow P, Puissant F, Delvigne A, Vanrysselberge M, Leroy F. Use of buserelin acetate in an in vitro. fertilization program: a comparison with classical clomiphene citrate-human menopausal gonadotropin treatment. Fertil Steril 1990;54: Hazout A, de Ziegler D, Cornel C, Fernandez H, Lelaidier C, Frydman R. Comparison of short 7 -day and prolonged treatment with gonadotropin-releasing hormone agonist desensitization for controlled ovarian hyperstimulation. Fertil Steril 1993;59: Hirschowitz JS, Soler NG, Wortsman J. Sex steroid levels during treatment of endometrio.sis. Obstet GynecoI1979;54: Steingold KA, Lu JKH, Judd HL, Meldrum DR. Danazol inhibits steroidogenesis by the human ovary in vivo. Fertil Steril 1986;45: Rannevik G. Hormonal, metabolic and clinical effects of danazol in the treatment of endometrio.sis. Postgrad Med J 1979;55: Tamaya T, Murakami T, Yamada T, Wada K, Fujimoto J, Okada H. Serum hormone and steroid hormone receptor levels during luteal-phase and lo.ng-term treatment with danazol. Fertil Steril 1983;40: Dmowski WP, Headley S, Radwanska E. Effects of danazol on pulsatile gonadotropin patterns and on serum estradiol levels in normally cycling women. Fertil Steril 1983;39: Jeppsson S, Mellquist P, Rannevik G. Short term effects of danazol on endometrial histology. Acta Obstet Gynecol Scand SuppI1984;123:41-4. Sakata et al. Hormone action of LA and danazol 437
An open randomized comparative study of the effect of goserelin depot and danazol in the treatment of endometriosis
FERTILITY AND STERILITY Copyright ~ 1992 The American Fertility Society Printed on acid-free paper in U.S.A. An open randomized comparative study of the effect of goserelin depot and danazol in the treatment
More informationAltered uterine artery blood flow impedance after danazol therapy: possible mode of action in dysfunctional uterine bleeding
FERTILITY AND STERILITY VOL. 72, NO. 1, JULY 1999 Copyright 1999 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Altered uterine artery
More informationTREATMENT OPTIONS FOR MALE HYPOGONADISM
TREATMENT OPTIONS FOR MALE HYPOGONADISM Bruce Biundo, RPh, FACA PCCA Pharmacy Consulting Department Updated July 2012 Hypogonadism in men is primarily a state involving lower than expected levels of testosterone,
More informationPros and Cons of Hormone Testing in Different Body Fluids with Different Routes of Hormone Delivery
Pros and Cons of Hormone Testing in Different Body Fluids with Different Routes of Hormone Delivery David T Zava, PhD ZRT laboratory A Guide to Steroid Hormone Testing in Different Body Fluids Following
More informationFree testosterone levels during danazol therapy*
FERTILITY AND STERILITY Copyright 1983 The American Fertility Society Printed in U.8A. Free testosterone levels during danazol therapy* Bo Nilsson, M.D. t:j: Ragnar Stidergard, Ph.D. Mats-GQran Damber,
More informationAndrogenes and Antiandrogenes
Androgenes and Antiandrogenes Androgens The androgens are a group of steroids that have anabolic and/or masculinizing effects in both males and females. Testosterone [tess-toss-terone], the most important
More informationA Randomized, Parallel, Comparative Study of the Efficacy and Safety of Nafarelin Versus Danazol in the Treatment of Endometriosis in Taiwan
ORIGINAL ARTICLE A Randomized, Parallel, Comparative Study of the Efficacy and Safety of Nafarelin Versus Danazol in the Treatment of Endometriosis in Taiwan Ming-Huei Cheng 1,2, Bill Ken-Jen Yu 1 4, Sheng-Ping
More informationAntti Kauppila, M.D. *t Sakari Telimaa, M.D.* Lars Ronnberg, M.D.* Juhani Vuori, B.A.:\:
FERTILITY AND STERILITY Copyright 1988 The American Fertility Society Printed in U.S.A. Placebo-controlled study on serum concentrations of CA-125 before and after treatment of endometriosis with danazol
More informationCHEMILUMINESCENCE ENZYME IMMUNOASSAY (CLIA) TESTOSTERONE. Testosterone. Cat #
DIAGNOSTIC AUTOMATION, INC. 21250 Califa Street, Suite 102 and 116, Woodland Hills, CA 91367 Tel: (818) 591-3030 Fax: (818) 591-8383 onestep@rapidtest.com technicalsupport@rapidtest.com www.rapidtest.com
More informationNolvadex. Nolvadex Functions & Traits: Effects of Nolvadex:
Nolvadex Nolvadex is a popular and powerfully effective Selective Estrogen Receptor Modulator (SERM) that is often referred to as an anti-estrogen. However, while being an antagonist it is also an agonist
More informationCHEMILUMINESCENCE IMMUNOASSAY (CLIA) Testosterone
DIAGNOSTIC AUTOMATION, INC. 21250 Califa Street, Suite 102 and 116, Woodland Hills, CA 91367 Tel: (818) 591-3030 Fax: (818) 591-8383 onestep@rapidtest.com technicalsupport@rapidtest.com www.rapidtest.com
More informationDr Tarza Jamal Pharmacology Lecture 2
Contraceptives and androgen hormone Contraceptives: Currently, interference with ovulation is the most common pharmacologic intervention for preventing pregnancy. Major classes of contraceptives 1. Combination
More informationUnderstanding combined oral contraception
Understanding combined oral contraception Paula Briggs, FFSRH Consultant in Community Sexual and Reproductive Health Southport and Ormskirk NHS Hospital Trust May Logan Centre, Bootle, L20 5DQ paulaeb@aol.com
More informationIssues. What is a low testosterone? Who needs testosterone therapy? Benefits/adverse effects of testosterone replacement Treatment options
Male Hypogonadism Jauch Symposium Waterloo, IA May 17, 2013 Janet A. Schlechte, M.D. Disclosure of Financial Relationships Janet A. Schlechte, M.D. has no relationships with any proprietary entity producing
More informationDanazol in the treatment of endometriosis: analysis of 100 cases with a 4-year follow-up
FERTILITY AND STERILITY Copyright c 1982 The American Fertility Society Vol. 37, No.6, June 1982 Printed in U.S A. Danazol in the treatment of endometriosis: analysis of 100 cases with a 4-year follow-up
More informationNatural estrogens estradiol estrone estriol
Estrogens Natural estrogens estradiol estrone estriol Nonsteroidal synthetic Diethylstilbestrol Chlorotrianisene Methallenestril Steroidal synthetic Ethinyl estradiol Mestranol Quinestrol To decrease some
More informationTestosterone Topical/Buccal/Nasal
BENEFIT APPLICATION Testosterone Topical/Buccal/Nasal DRUG POLICY Benefit determinations are based on the applicable contract language in effect at the time the services were rendered. Exclusions, limitations
More informationTESTOFEN. Anabolic & Androgenic Activity GENCOR PACIFIC, INC. Fenugreek Extract standardized for FENUSIDE TM. Copyright 2005 by Gencor Pacific, Inc.
GENCOR PACIFIC, INC. 920E. Orangethorpe Avenue, Suite B, Anaheim, CA. 92801 Ph: 714.870.8723 714.870.8724 efax: 732.875.0306 drjit@gencorpacific.com manu@gencorpacific.com www.gencorpacific.com TESTOFEN
More informationTreatment of endometriosis with danazol: report of a 6-year prospective study
FERTILITY AND STERILITY Copyright < 1985 The American Fertility Society Vol. 43 No.3 March 1985 Printed In U.S.A. Treatment of endometriosis with danazol: report of a 6-year prospective study Veasy C Buttram
More informationUpdates on Anti-doping and TUE Management in Paralympic Sport
International Paralympic Committee Updates on Anti-doping and TUE Management in Paralympic Sport Matthew Fedoruk, Ph.D. March 15, 2018 PyeongChang 2018 IPC Medical / Sports Science Committee Workshops
More informationReproductive DHT Analyte Information
Reproductive DHT Analyte Information - 1 - DHT Introduction Dihydrotestosterone (DHT) together with other important steroid hormones such as testosterone, androstenedione (ASD) and dehydroepiandrosterone
More informationMI Androgen Deficiency Hypogonadism
MI Androgen Deficiency Hypogonadism WADA TUE Expert Group John A Lombardo, MD October 2014, Columbus, Ohio USA Hypothalamic-Pituitary-Gonadal Axis / 2 Hypogonadism/Androgen Deficiency Clinical syndrome:
More informationHastening the onset of the breeding season. by Julie Skaife, of Select Breeders Services
Hastening the onset of the breeding season. by Julie Skaife, of Select Breeders Services The horse is a seasonal breeder meaning that natural mating occurs during certain times of the year to ensure that
More informationAlthough women produce only
For mass reproduction, content licensing and permissions contact Dowden Health Media. Mary Lake Polan, MD, PhD, MPH Katharine Dexter McCormick and Stanley McCormick Memorial Professor and Chair Emeritus,
More informationTestosterone Hormone Replacement Drug Class Prior Authorization Protocol
Testosterone Hormone Replacement Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective date: April 1, 2018 This policy has been developed through
More informationAffirming Care of the Transgender Patient
Mountain West AIDS Education and Training Center Affirming Care of the Transgender Patient Jessica Rongitsch, MD, FACP This presentation is intended for educational use only, and does not in any way constitute
More informationSecrets of Abang Sado : Effects of testosterone therapy. Azraai Nasruddin
+ Secrets of Abang Sado : Effects of testosterone therapy Azraai Nasruddin + Testosterone Testosterone : Steroid hormone - Made primarily by the testicles in males - Small amounts produced by the adrenal
More information* Presented in part at the 37th Japanese Congress of Fertility and Sterility, Tokyo, Japan, November 6 to 7, 1992.
FERTILITY AND STERILITY Copyright 1995 Amerian Soiety for Reprodutive Mediine Vol. 63. No.6, June 1995 Printed on aid-free paper in U. S. A. Danazol onentrations in ovary, uterus, and serum and their effet
More informationSue Marty, Ph.D., D.A.B.T. The Dow Chemical Company TERA Endocrine Workshop April 23, 2013
Sue Marty, Ph.D., D.A.B.T. The Dow Chemical Company TERA Endocrine Workshop April 23, 2013 Agenda Value of WoE/MoA determinations in EDSP Information used to examine potential endocrine activity and/or
More informationEffect of Maternal Drug Treatment during Pregnancy and Lactation Oxymetholone through the Levels of Sex Hormones in Adult Female Offspring Rats
Advances in Environmental Biology, 6(10): 2791-2795, 2012 ISSN 1995-0756 2791 This is a refereed journal and all articles are professionally screened and reviewed ORIGINAL ARTICLE Effect of Maternal Drug
More informationInitial trial of slow-release testosterone microspheres in hypogonadal men*
FERTILITY AND STERILITY Copyright c 1988 The American Fertility Society Printed in U.S.A. Initial trial of slow-release testosterone microspheres in hypogonadal men* Allen S. Burris, M.D. t Larry L. Ewing,
More informationDonald W. Morrish, MD, PhD, FRCPC Presented at Mountain Man: Men's Health Conference, May Terry s Testosterone
Focus on CME at University of Alberta ADAM: Dealing with the Decline Donald W. Morrish, MD, PhD, FRCPC Presented at Mountain Man: Men's Health Conference, May 2005 We now know there is a decline in total
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.CPA.291 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory
More informationNatural Hair Transplant Medical Center, Inc Dove Street, Suite #250, Newport Beach, CA Phone
Natural Hair Transplant Medical Center, Inc. 1000 Dove Street, Suite #250, Newport Beach, CA 92660 Phone-949-622-6969 Finasteride (PROPECIA ) Acknowledgement Finasteride is an oral medication, manufactured
More informationSkin metabolism of steroid hormones as endogenous compounds?
Skin metabolism of steroid hormones as endogenous compounds? Van Luu-The Department of Molecular Medicine Laval University Québec, Canada This work has been supported by L Oréal Research Steroid hormones
More informationCLINICAL ASSESSMENT AND DIAGNOSIS
FERTILITY AND STERILITY VOL. 77, NO. 4, SUPPL 4, APRIL 2002 Copyright 2002 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. CLINICAL ASSESSMENT
More informationDrug Class Monograph
Drug Class Monograph Class: Testosterone Hormone Replacement Drug: Androderm (testosterone transdermal system), Androgel (testosterone topical gel), Axiron (testosterone topical solution), Aveed (testosterone
More informationbiosensis Mouse CXCL10/IP-10 ELISA Kit Protocol
biosensis Mouse CXCL10/IP-10 ELISA Kit Protocol Catalogue No: BEK-2124-2P TABLE OF CONTENTS I Materials provided...2 II Equipment required but not supplied...2 III Technical hints....2 IV Storage of kit
More informationMIE KAMIYA Laboratory of Physiology, Ocean Research Institute, University of Tokyo, Nakano, Tokyo
Endocrinol. Japon. 1972, 19 (5), 489 `493 NOTE Hormonal Effect on Na-K-ATPase Activity in the Gill of Japanese Eel, Anguilla Japonica, with Special Reference to Seawater Adaptation MIE KAMIYA Laboratory
More informationPRODUCT INFORMATION TESTOVIRON DEPOT. (testosterone enanthate)
PRODUCT INFORMATION TESTOVIRON DEPOT (testosterone enanthate) NAME OF THE MEDICINE Testosterone enanthate is designated chemically as 17 beta-heptanoyloxy-4-androstene-3- one. The empirical formula of
More informationANNEX 3 TO THE DRAFT REPORT OF THE OECD VALIDATION OF THE RAT HERSHBERGER BIOASSAY: PHASE 2
ANNEX 3 TO THE DRAFT REPORT OF THE OECD VALIDATION OF THE RAT HERSHBERGER BIOASSAY: PHASE 2 Hershberger Assay Interlaboratory Study: Statistical analysis of phase 2 data from 16 laboratories in the multi-chemical
More informationFemale testosterone level chart
Female testosterone level chart The Borg System is 100 % Female testosterone level chart Mar 23, 2015. Male, Female. Age: T Level (ng/dl):, Age: T Level (ng/dl):. 0-5 mo. 75-400, 0-5 mo. 20-80. 6 mos.-9
More informationEstrogens & androgens ا.م.د.اسامة ايوب lec:4-6
Estrogens & androgens ا.م.د.اسامة ايوب lec:4-6 Sex hormones produced by the gonads are necessary for conception embryonic maturation, and development of primary and secondary sexual characteristics at
More information1.) Take an alcohol swab to the stopper of both your peptide vial and the vial of the dilutent.
Peptide Guide Peptide Information Peptides come in the form of lyophilized (freeze dried) powder. The amount of powder/product is stated in International Units (IU's) or in Milligrams (mg). Melanotan peptides
More informationCONFÉRENCE À SUCCÈS EN SCIENCES DE LA VIE : ENDOCEUTICS
CONFÉRENCE À SUCCÈS EN SCIENCES DE LA VIE : ENDOCEUTICS 13 Septembre 2018 Quebec, Canada 1 ENDOCEUTICS No. 1 Innovative pharmaceutical company in menopausal women s health in the world 2 Facilities Head
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Androgens and Anabolic Steroids Page 1 of 57 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Androgens and Anabolic Steroids Prime Therapeutics will review Prior
More informationAndrogens and Anabolic Steroids Prior Authorization with Quantity Limit - Through Preferred Topical Androgen Agent
Androgens and Anabolic Steroids Prior Authorization with Quantity Limit - Through Preferred Topical Androgen Agent Androgens/Anabolic Steroids Prior Authorization with Quantity Limit Through Preferred
More informationTestosterone Hormone Replacement Drug Class Prior Authorization Protocol
Line of business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 Testosterone Hormone Replacement Drug Class Prior Authorization Protocol This policy has been developed through
More informationHUMAN IL6 KITS PROTOCOL
HUMAN IL6 KITS PROTOCOL Part # 62HIL06PEG & 62HIL06PEH Test size: 500 tests (62HIL06PEG), 10,000 tests (62HIL06PEH) - assay volume: 20 µl Revision: 04 (Jan. 2018) Store at: -60 C or below This product
More information1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING
SAFETY DATA SHEET 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING Product identifier ZOLADEX FOR DEPOT/IMPLANT Details of the supplier of the safety data sheet : ASTRAZENECA PTY
More informationAntiduretic Hormone, Growth. Hormone & Anabolic Steroids
Goudarz Sadeghi, DVM, PhD, DSc Associate Professor of Pharmacology University of Tehran Faculty of Veterinary Medicine Veterinary Pharmacology Endocrine System Antiduretic Hormone, Growth Hormone & Anabolic
More informationbiosensis Rat Fibronectin ELISA Kit Protocol
biosensis Rat Fibronectin ELISA Kit Protocol Catalog No: BEK-2017-2P For quantitative detection of rat Fibronectin in cell culture supernatants, serum, and citrate, heparin, or EDTA plasma samples only
More informationTESTOFEN HUMAN CLINICAL TRIAL GENCOR PACIFIC, INC. Copyright 2006 by Gencor Pacific, Inc.
GENCOR PACIFIC, INC. 920 E. Orangethorpe Avenue, Suite B, Anaheim, CA 92801 Ph: 714.870.8723 714.870.8724 efax: 732.875.0306 drjit@gencorpacific.com gita@gencorpacific.com www.gencorpacific.com TESTOFEN
More informationThe physiology of normal androgen production in
Mayo Clin Proc, April 2004, Vol 79 (Supplement) Formulations and Use of Androgens S3 Supplement Article Formulations and Use of Androgens in Women MICHELINE C. CHU, MD, AND ROGERIO A. LOBO, MD The physiology
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Implantable Hormone Pellets Table of Contents Coverage Policy... 1 General Background... 3 Coding/Billing Information... 5 References... 6 Effective Date...
More informationDANAZOL SUPPRESSES LUTEAL FUNCTION IN VITRO AND IN VIVO
FERTILITY AND STERILITY Copyright 1980 The American Fertility Society Vol. 33, No.5, May 191!0 Printed in U.SA. DANAZOL SUPPRESSES LUTEAL FUNCTION IN VITRO AND IN VIVO KEITH M. HENDERSON, PH.D.* BENJAMIN
More informationab Androstenedione ELISA Kit
ab108672 Androstenedione ELISA Kit Instructions for Use A competitive immunoenzymatic assay for the quantitative measurement of Androstenedione in serum and plasma (citrate). This product is for research
More informationIcd-10 low levels of testosterone
Icd-10 low levels of testosterone The Borg System is 100 % Icd-10 low levels of testosterone 1-10-2017 if your hormone levels are too high or too low, you may have a hormone disorder. Hormone diseases
More informationsocial impairment. The following exclusion criteria applied: age under 18 years; weight under 45 kg or over 80 kg;
Postgrad Med J (1991) 67, 450-454 The Fellowship of Postgraduate Medicine, 1991 Low dose danazol in the treatment of the premenstrual syndrome Miriam Deeny, Robert Hawthorn and D. McKay Hart Division ofobstetrics
More informationMonitoring Hormone Therapy Mark Newman, M.S. President of Precision Analytical Inc.
Mr Mark Newman Monitoring Hormone Therapy Mark Newman, M.S. President of Precision Analytical Inc. 2 Avoiding Pitfalls in (B)HRT Monitoring and Picking the Right Lab Test Objectives: Outline how expected
More informationbiosensis Human IGF-II, Insulin-like growth factor II, Somatomedin-A ELISA Kit Protocol
biosensis Human IGF-II, Insulin-like growth factor II, Somatomedin-A ELISA Kit Protocol Catalog No: BEK-2029-1P For quantitative detection of human IGF-II in cell culture supernatants, cell lysates, tissue
More informationM0BCore Safety Profile. Pharmaceutical form(s)/strength: 5 mg SE/H/PSUR/0002/006 Date of FAR:
M0BCore Safety Profile Active substance: Finasteride Pharmaceutical form(s)/strength: 5 mg P-RMS: SE/H/PSUR/0002/006 Date of FAR: 16.05.2014 4.3 Contraindications Finasteride is not indicated for use in
More informationbiosensis Human TNFα/Cachectin/TNFSF2 ELISA Kit Protocol
biosensis Human TNFα/Cachectin/TNFSF2 ELISA Kit Protocol Catalog No: BEK-2100-1P For quantitative detection of human TNFα in cell culture supernatants, serum, and heparin, EDTA or citrate treated plasma
More informationHGH for Sale Natural Anti-Aging Human Growth Hormone
HGH for Sale Natural Anti-Aging Human Growth Hormone Human growth hormone is one of the hottest supplement trends on the market, and now you can purchase top-quality HGH to be delivered right to your home!
More informationPackage Leaflet: Information for the patient. Sustanon 250, 250 mg/ml, solution for injection (testosterone esters)
Package Leaflet: Information for the patient Sustanon 250, 250 mg/ml, solution for injection (testosterone esters) Read all of this leaflet carefully before you start using this medicine because it contains
More informationComparison of Efficacy of Norethisterone (Primolut-N) Between Twice or Thrice Daily Dose to Avoid Menstrual
Comparison of Efficacy of Norethisterone (Primolut-N) Between Twice or Thrice Daily Dose to Avoid Menstrual Comparison of Efficacy of Norethisterone (Primolut-N) Between Twice or Thrice Daily Dose to Avoid
More informationSUMMACARE COMMERCIAL MEDICATION REQUEST GUIDELINES TESTOSTERON. Generic Brand HICL GCN Exception/Other ROUTE MISCELL.
Generic Brand HICL GCN Exception/Other ANDRODERM 01403 ROUTE MISCELL. ANDROGEL AXIRON FORTESTA NATESTO STRIANT TESTIM VOGELXO DEPO- 01400 ROUTE MISCELL. CYPIONATE TESTOSTERON E GCN 38586 DELATESTRYL 01401
More informationbiosensis Human Soluble Tumor Necrosis Factor receptor type II (stnfrii) ELISA Kit Protocol
biosensis Human Soluble Tumor Necrosis Factor receptor type II (stnfrii) ELISA Kit Protocol Catalog No: BEK-2103-2P For quantitative detection of human soluble TNFRII (stnfrii) in human cell culture supernatants,
More informationMSD 96-Well MULTI-ARRAY and MULTI-SPOT Human Granulocyte Colony Stimulating Factor (hg-csf) Ultrasensitive Assay
MSD 96-Well MULTI-ARRAY and MULTI-SPOT Human Granulocyte Colony Stimulating Factor (hg-csf) Ultrasensitive Assay Summary This assay measures Human Granulocyte Colony Stimulating Factor (G-CSF) in a 96-well
More informationOnce malignancy and significant pelvic pathology
CHAPTER 3 Medical Treatment OVERVIEW Once malignancy and significant pelvic pathology have been ruled out, medical treatment should be considered as the first line therapeutic option for abnormal uterine
More informationDanazol apollo
Danazol apollo +9191 46 950 950 Danazol apollo +9191 46 950 950 Danazol CAS Number : 17230-88-5 Molecular Weight : 337.46 g/mol Molecular Formula : C22H27NO2 Systematic (IUPAC) : (1S,2R,13R,14S,17R,18S)-17-
More informationClinical impact of type I and type II 5 alpha-reductase inhibition in prostatic disease: review and update 아주대학교김선일
Clinical impact of type I and type II 5 alpha-reductase inhibition in prostatic disease: review and update 아주대학교김선일 Development of 5ARI Discovery of 5AR type I and type II Pharmacodynamic and pharmacokinetic
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Androgens and Anabolic Steroids Page 1 of 53 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Androgens and Anabolic Steroids Prime Therapeutics will review Prior
More informationbiosensis Mouse Brain-derived neurotrophic factor (BDNF) ELISA Kit Protocol
biosensis Mouse Brain-derived neurotrophic factor (BDNF) ELISA Kit Protocol Catalog No: BEK-2003-2P For quantitative detection of mouse BDNF in cell culture supernatants, cell lysates, serum, and citrate,
More informationDanazol and gestagen displacement of testosterone and influence on sex-hormone-binding globulin capacity*
FERTILITY AND STERILITY Copyright c 1982 The American Fertility Society Printed in U.8A. Danazol and gestagen displacement of testosterone and influence on sex-hormone-binding globulin capacity* Bo Nilsson,
More informationMedical treatment of symptomatic endometriosis
Medical treatment of symptomatic endometriosis Ulrich Cirkel Department of Obstetrics and Gynecology, University Hospital Muenster, AlbertSchweitzerStraBe 33, 48129 Muenster, Germany The concept of endometriosis
More informationbiosensis Human Lipocalin-2/NGAL ELISA Kit Protocol
biosensis Human Lipocalin-2/NGAL ELISA Kit Protocol Catalog No: BEK-2141-2P For quantitative detection of human Lipocalin-2 in cell culture supernatants, serum, and heparin treated plasma, saliva, and
More informationRobert Perlstein, M.D. Medical Officer. Center for Drug Evaluation and Research. U.S. Food & Drug Administration
-------------------- Robert Perlstein, M.D. Medical Officer Center for Drug Evaluation and Research U.S. Food & Drug Administration -------------------- Sentencing of Food and Drug Offenses Before the
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
Generic Brand HICL GCN Exception/Other METHYL ANDROID METHITEST METHYL TESTRED 01404 ROUTE MISCELL. CYPIONATE ENANTHATE GUIDELINES FOR USE ANDRODERM ANDROGEL AXIRON FORTESTA NATESTO STRIANT TESTIM VOGELXO
More informationbiosensis Mouse Vascular endothelial growth factor A/VEGF-A/VEGF-164/VEGF-1/VEGF- 120/VEGF-2 ELISA Kit Protocol
biosensis Mouse Vascular endothelial growth factor A/VEGF-A/VEGF-164/VEGF-1/VEGF- 120/VEGF-2 ELISA Kit Protocol Catalog No: BEK-2110-1P For quantitative detection of mouse VEGF-A (VEGF164&VEGF120) in mouse
More informationDevelopment of a Clinical Research Method for the Measurement of Testosterone. Dihydrotestosterone
Development of a Clinical Research Method for the Measurement of Testosterone and Dihydrotestosterone Martijn van Faassen, Maarten van den Noort and Ido Kima University Medical Center, Groningen, Netherlands
More informationIcd 10 hormone replacement therapy male
Icd 10 hormone replacement therapy male 2018 ICD - 10 code for Hormone replacement therapy is Z79.890. Lookup the complete ICD 10 Code details for Z79.890. The ICD - 10 system requires that. TEENren who
More informationHealth Products Regulatory Authority
1 NAME OF THE VETERINARY MEDICINAL PRODUCT Myodine 25 mg/ml solution for injection for dogs and cats 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: Active substance: Nandrodine laurate 25
More informationAdverse effects of anabolic androgenic steroids abuse on gonadal function, glucose homeostasis and cardiovascular function
Adverse effects of anabolic androgenic steroids abuse on gonadal function, glucose homeostasis and cardiovascular function Associate Professor Caroline Kistorp, Ph.D Department of Internal Medicine, Herlev
More informationPaul J. Perry, 1,3 * John H. MacIndoe, 2 William R. Yates, 1 Shane D. Scott, 3 and Timothy L. Holman 1. Toxicology
Clinical Chemistry 43:5 731 735 (1997) Drug Monitoring and Toxicology Detection of anabolic steroid administration: ratio of urinary testosterone to epitestosterone vs the ratio of urinary testosterone
More informationPharmacology 10 بسم هللا الرحمن ارحيم. Androgens and antiandrogens
بسم هللا الرحمن ارحيم Androgens and antiandrogens The androgens are a group of steroids that have anabolic and/or masculinizing effects in both males and females. Testosterone, the most important androgen
More informationDoping in Sports: Catching and Preventing It An Expert Interview With Gary I. Wadler, MD
Doping in Sports: Catching and Preventing It An Expert Interview With Gary I. Wadler, MD Carol Peckham; Gary I. Wadler, MD As part of our coverage of the 2012 Olympics, Medscape interviewed Gary I. Wadler,
More informationSIMPLE, EFFICIENT AND SIMULTANEOUS DETERMINATION OF ANABOLIC STEROIDS IN HUMAN URINE
SIMPLE, EFFICIENT AND SIMULTANEOUS DETERMINATION OF ANABOLIC STEROIDS IN HUMAN URINE Pages with reference to book, From 216 To 218 S.J. Khurshid, M. Riaz, S. Ahmed ( Nuclear Chemistry Division, Pakistan
More informationPolicy. covered: bilateral. alcohol or. Approve. 3. Palliative enanthate injection in. women for. 6 months if. can also sponsive tumor.
Injectablee Testosterone Products Prior Authorization Policy Number: 5.01.597 Origination: 07/2014 Last Review: 07/2014 Next Review: 07/2015 Policy BCBSKC will provide coverage for injectable testosterone
More information*Dr. Mushreq Aziz Tnesh AL-Lamy, **Dr. Asaad Adnan Aziz Al-Safi. *, ** Physical Education College /Al-Qadisiyah University ABSTRACT
EFFECT OF THE ABUSE OF STEROIDAL ANDRO- GENIC HORMONES AND THEIR RELATIVE CONTRI- BUTION TO THE LEVEL OF HORMONES (TESTOS- TERONE, FSH, LH) AND THE PROPORTION OF IN- FERTILITY IN BODYBUILDERS *Dr. Mushreq
More informationJOSEPH W. GOLDZIEHER, M,D.t C, BRANDON CHENAULT, M.D. ARMANDO DE LA PENA, M.S. TAZEWELL S. DOZIEIt DUANE C. KRAEMER, D.V.M., PH.D.
FERTILITY AND STERILITY Copyright,< 1978 The American Fertility Society Vol. 29, No.4, April 1978 Printed in U.SA. COMPARATIVE STUDIES OF THE ETHYNYL ESTROGENS USED IN ORAL CONTRACEPTIVES: EFFECTS WITH
More information1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING. : ASTRAZENECA P.O. Box Wilmington, DE USA
SAFETY DATA SHEET 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING Product identifier ZOLADEX FOR DEPOT/IMPLANT Details of the supplier of the safety data sheet : ASTRAZENECA P.O.
More informationMartina Dören, M.D., a Alexander Rübig, M.D., b Herjan J. T. Coelingh Bennink, M.D., c and Wolfgang Holzgreve, M.D. d
FERTILITY AND STERILITY VOL. 75, NO. 3, MARCH 2001 Copyright 2001 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Differential effects
More informationMALE HORMONE THERAPY OPTIONS
MALE HORMONE THERAPY OPTIONS The following tables have been compiled by Women s staff pharmacists to represent some of the more frequently prescribed regimens for men. The Women s logo is placed throughout
More informationOriginal Research Declining testicular function in aging men
(2003) 15, Suppl 4, S3 S8 & 2003 Nature Publishing Group All rights reserved 0955-9930/03 $25.00 www.nature.com/ijir Original Research 1 * 1 Wesley Woods Health Center, Atlanta, Georgia, USA Age-related
More informationPRODUCT INFORMATION PRIMOTESTON DEPOT. (testosterone enantate)
PRODUCT INFORMATION PRIMOTESTON DEPOT (testosterone enantate) NAME OF THE MEDICINE Testosterone enantate is designated chemically as 17 beta-heptanoyloxy-4-androstene-3- one. The empirical formula of testosterone
More informationThe ICL Insider. Lab Testing: Testosterone. In This Issue. The Debate
The ICL Insider February 2017 Volume 2, Issue 2 Lab Testing: Testosterone In This Issue Testosterone shashtilak@iclabs.ca Next Issue: Expected Release April 2017 The Debate Aging is accompanied by various
More informationThe Effect of Low Level He-Ne Laser on Spawning Behavior in Common Carp Fish Cyprinus carpio
American Journal of Biology and Life Sciences 2015; 3(6): 218-222 Published online October 13, 2015 (http://www.openscienceonline.com/journal/ajbls) The Effect of Low Level He-Ne Laser on Spawning Behavior
More informationTESTOVIRON 300 TESTOCYP 200 INJECTABLE PRODUCTS
Platinum Biotech has a commitment to all people, a commitment of improving the quality of life for each and every person worldwide, through which we constantly strive to innovate, improve and increase
More informationThe Testosterone Quandary. Beth Crowder, PhD, APRN
The Testosterone Quandary Beth Crowder, PhD, APRN Objectives Define testosterone, the hypothalamic-pituitary-gonadotrophic axis, and normal blood levels List functions of testosterone and symptoms of low
More information